Location of Repository

Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease

By Sarah L. Hands, Robert Mason, M. Umar Sajjad, Flaviano Giorgini and Andreas Wyttenbach

Abstract

HD (Huntington's disease) is caused by a polyQ (polyglutamine) expansion in the huntingtin protein, which leads to protein misfolding and aggregation of this protein. Abnormal copper accumulation in the HD brain was first reported more than 15 years ago. Recent findings show that copper-regulatory genes are induced during HD and copper binds to an N-terminal fragment of huntingtin, supporting the involvement of abnormal copper metabolism in HD. We have demonstrated that in vitro copper accelerates the fibrillization of an N-terminal fragment of huntingtin with an expanded polyQ stretch (httExon1). As we found that copper also increases polyQ aggregation and toxicity in mammalian cells expressing httExon1, we investigated further whether overexpression of genes involved in copper metabolism, notably MTs (metallothioneins) known to bind copper, protect against httExon1 toxicity. Using a yeast model of HD, we have shown that overexpression of several genes involved in copper metabolism reduces polyQ-mediated toxicity. Overexpression of MT-3 in mammalian cells significantly reduced polyQ aggregation and toxicity. We propose that copper-binding and/or -chaperoning proteins, especially MTs, are potential therapeutic targets for HD

Publisher: Portland Press
Year: 2010
DOI identifier: 10.1042/BST0380552
OAI identifier: oai:lra.le.ac.uk:2381/8037
Journal:

Suggested articles

Preview

Citations

  1. (2005). A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. doi
  2. (2008). Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. doi
  3. (1999). Cu(II) Potentiation of Alzheimer Abeta Neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. doi
  4. (2008). Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry. doi
  5. (2005). Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. doi
  6. (2007). Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity. doi
  7. (2006). Regional and cellular gene expression changes in human Huntington's disease brain.
  8. (1993). The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.